NCT03193671 is a clinical trial of Diagnosis in Ovarian Neoplasms, sponsored by Göteborg University.

Who is sponsoring NCT03193671?

NCT03193671 is sponsored by Göteborg University.

What drugs are being tested in NCT03193671?

Interventions in NCT03193671: Diagnosis.

What condition does NCT03193671 study?

NCT03193671 studies Ovarian Neoplasms, Diagnoses Disease, Biomarkers, Algorithms.

Is NCT03193671 still recruiting?

NCT03193671 is currently completed. Last updated 29 August 2017.

Last reviewed 2017-08-29 · How we verify

NCT03193671

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis

Completed Last updated 29 August 2017

What this trial tests

trial testing Diagnosis in Ovarian Neoplasms in 684 participants. Completed in 29 February 2016.

Timeline

1 September 2013

Primary endpoint
29 February 2016

29 February 2016

Quick facts

Lead sponsor	Göteborg University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	684
Start date	1 September 2013
Primary completion	29 February 2016
Estimated completion	29 February 2016
Sites	1 location across Sweden

Drugs / interventions tested

Diagnosis

Conditions studied

Ovarian Neoplasms — all drugs for Ovarian Neoplasms →
Diagnoses Disease — all drugs for Diagnoses Disease →
Biomarkers — all drugs for Biomarkers →
Algorithms — all drugs for Algorithms →

Sponsor

Göteborg University

Who can join

18 and older, female only, with Ovarian Neoplasms or Diagnoses Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the biomarkers CA125 and HE4 and the algorithms RMI and ROMA on a normal population in the western region of Sweden. The aim is to improve diagnosis of ovarian cancer. If the investigators observe a clear improvement in the early diagnosis of EOC, the investigators aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of Sweden.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics.
Lycke M, Ulfenborg B, Malchau Lauesgaard J, Kristjansdottir B, et al · · 2021 · cited 34× · PMID 34388324 · DOI 10.1515/cclm-2021-0510
Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers.
Lycke M, Ulfenborg B, Kristjansdottir B, Sundfeldt K. · · 2020 · cited 7× · PMID 31973047 · DOI 10.3390/jcm9020299

Verify or expand the search:

Other trials of Diagnosis

Trials testing the same drug.

NCT06038773 — Social and Clinical Aspects of Pelvic Pain in Turkey · completed
NCT06514482 — Spanish Registry of Patients With Sleep Apnea and Daytime Sleepiness · recruiting
NCT05678296 — Investigation of Effectiveness of Local Antibiotic With Platelet Rich Fibrin on Third Molar Surgery Outcomes In Vivo · completed
NCT04989127 — Comparison The Postoperative Effects of Local and Systemic Antibiotics Applied With Platelets Rich Fibrin · completed
NCT03734978 — Association Between Different Blood Groups and Sepsis in Preterm Infants · unknown

Other recruiting trials for Ovarian Neoplasms

Currently open trials in the same condition.

NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting

Other Göteborg University trials

Trials by the same sponsor.

NCT07260604 — HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM) · NA · not yet recruiting
NCT07401420 — Life Sustaining Treatments in Critically Ill Children · not yet recruiting
NCT07213245 — Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) · NA · recruiting
NCT07178405 — Effects of Meal Characteristics on Appetite · NA · completed
NCT07172841 — Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03193671 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Göteborg University
Last refreshed: 29 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03193671.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing